Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non-Small-Cell Lung Cancer
Journal of Clinical Oncology, 12/01/2011
Clinical Article
Scagliotti GV et al. – The most common grade 3 or 4 chemotherapy–related adverse events were neutropenia and thrombocytopenia. No treatment–by–histology interaction effect was apparent. Although the study was terminated early, preoperative gemcitabine plus cisplatin followed by radical surgery improved survival in patients with clinical stage IIB/IIIA non–small–cell lung cancer (NSCLC).
